The Research Institute of the Germans Trias i Pujol Hospital demonstrates how personalised medicine helps to control the effects of acromegaly earlier
IGTP leading the first study in the world to prove that personalised therapies are more effective than classic drugs indicated for the treatment of this rare hormonal disease. It is based on response biomarkers that, depending on what they indicate, allow the best possible treatment to be assigned earlier. In addition to very noticeable facial and skeletal deformities, acromegaly causes severe alterations in other parts of the body. Published in The Journal of Clinical Endocrinology & Metabolism.